sb 203580 has been researched along with vx-745 in 17 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (vx-745) | Trials (vx-745) | Recent Studies (post-2010) (vx-745) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 58 | 1 | 35 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, JW; Cameron, PM; Fitzgerald, CE; O'Keefe, SJ; Patel, SB; Pikounis, VB; Scapin, G; Zaller, D | 1 |
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Bookland, RG; Brugel, TA; Clark, MP; De, B; Golebiowski, A; Hsieh, LC; Janusz, MJ; Laufersweiler, MJ; Laughlin, SK; Maier, J; Mekel, MJ; Sabat, M; Vanrens, JC; Walter, RL | 1 |
| Bagley, MC; Davis, T; Dix, MC; Kipling, D; Rokicki, MJ | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Boman, E; Ceide, SC; Chang, CD; Dahl, R; Dalesandro, D; Delaet, NG; Erb, E; Ernst, JT; Gibbs, A; Kahl, J; Kessler, L; Larson, CJ; Lundström, J; Miller, S; Montalban, AG; Nakanishi, H; Roberts, E; Saiah, E; Sullivan, R; Wang, Z | 1 |
| Alvira, E; Benson, AG; Blevis-Bal, R; Boehm, TL; Christie, L; Devadas, B; Devraj, RV; Durley, RC; Hepperle, M; Hickory, BS; Hitchcock, J; Jerome, KD; Kurumbail, R; Madsen, HM; Marrufo, LD; Monahan, JB; Naing, W; Owen, TJ; Promo, MA; Rucker, PV; Selness, SR; Shieh, H; Walker, JK; Xing, L | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Russu, WA; Shallal, HM | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bellon, SF; Bemis, GW; Chen, G; Cochran, JE; Duffy, JP; Evindar, G; Ford, PJ; Galullo, VP; Gao, H; Germann, UA; Green, J; Harrington, EM; Huang, C; Jones, P; Murcko, MA; Pazhanisamy, S; Salituro, FG; Su, MS; Taslimi, P; Wang, YM; Wilson, KP | 1 |
| Anderson, WF; Arancio, O; Chico, LW; Minasov, G; Pelletier, JC; Roy, SM; Van Eldik, LJ; Watterson, DM | 1 |
| Laufer, S; Wagner, G | 1 |
| Azevedo, R; de Vlieg, J; Kazemier, B; Oubrie, A; Raaijmakers, H; van Zeeland, M | 1 |
| Arthur, JS; Aubareda, A; Batty, IH; Boothby, M; Crowe, J; Dean, JL; Gaestel, M; Gray, A; Lee, K; Leslie, NR; McGuire, VA; Monk, CE; O'Keefe, SJ; Ronkina, N; Santos, SG; Schwermann, J | 1 |
| Dastidar, SG; Diwan, M; Najmi, AK; Singh, RK | 1 |
2 review(s) available for sb 203580 and vx-745
| Article | Year |
|---|---|
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.
Topics: Animals; Brain; Cognitive Dysfunction; Humans; Inflammation; Nervous System Diseases; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors | 2019 |
Small molecular anti-cytokine agents.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Caspase Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytokines; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridazines; Pyridines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Succinates; Thiazoles; Tumor Necrosis Factor-alpha; Urea | 2006 |
15 other study(ies) available for sb 203580 and vx-745
| Article | Year |
|---|---|
Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity.
Topics: Amino Acid Sequence; Animals; Cloning, Molecular; Enzyme Inhibitors; Glycine; Imidazoles; Inhibitory Concentration 50; Kinetics; Mice; Mitogen-Activated Protein Kinase 14; Mitogen-Activated Protein Kinases; Models, Chemical; Models, Molecular; Molecular Sequence Data; Mutation; Peptides; Protein Binding; Protein Isoforms; Protein Structure, Tertiary; Pyridazines; Pyridines; Pyrimidines; Quinazolines; Sequence Homology, Amino Acid | 2003 |
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.
Topics: Cell Line; Chemistry, Pharmaceutical; Crystallography, X-Ray; Drug Design; Humans; Lipopolysaccharides; Models, Chemical; Models, Molecular; p38 Mitogen-Activated Protein Kinases; Purines; Tumor Necrosis Factor-alpha | 2006 |
Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells.
Topics: Blotting, Western; Enzyme-Linked Immunosorbent Assay; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Werner Syndrome | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Topics: Adenosine Triphosphate; Allosteric Site; Amides; Animals; Binding Sites; Cells, Cultured; Crystallography, X-Ray; Drug Design; Humans; Lipopolysaccharides; Models, Molecular; Molecular Structure; Monocytes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Rats; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2008 |
Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Drug Discovery; Humans; JNK Mitogen-Activated Protein Kinases; Male; Microsomes, Liver; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridones; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2009 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.
Topics: | 2011 |
X-ray structure of p38α bound to TAK-715: comparison with three classic inhibitors.
Topics: Adenosine Triphosphate; Benzamides; Catalytic Domain; Cloning, Molecular; Crystallization; Crystallography, X-Ray; Humans; Imidazoles; Indoles; Ligands; p38 Mitogen-Activated Protein Kinases; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Pyridazines; Pyridines; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2012 |
Cross talk between the Akt and p38α pathways in macrophages downstream of Toll-like receptor signaling.
Topics: Animals; Cell Line; Enzyme Activation; Heat-Shock Proteins; Imidazoles; Intracellular Signaling Peptides and Proteins; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinase 14; Molecular Chaperones; Neoplasm Proteins; Phosphatidylinositol Phosphates; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyridazines; Pyridines; Pyrimidines; Receptor Cross-Talk; Signal Transduction; Toll-Like Receptors | 2013 |
Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro.
Topics: Anti-Inflammatory Agents; Biomarkers; Cell Survival; Cells, Cultured; Cytokines; Hep G2 Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Inflammation; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Lipopolysaccharides; MAP Kinase Kinase 4; Naphthalenes; Nitric Oxide; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; THP-1 Cells; U937 Cells | 2018 |